DT-168

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

7mo

DSGNPhase 2$604M

DT-168 Phase 2 Results Expected

DT-168• Fuchs Endothelial Corneal Dystrophy28

Sep 15Estimated

00%

Competitive Landscape

0 competitors in Fuchs Endothelial Corneal Dystrophy

Drug Information

Target Indication

Fuchs Endothelial Corneal Dystrophy

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

DSGN

Design Therapeutics, Inc.

Related Pipeline

Friedreich Ataxia